Guillermo de Velasco1, Axel Bex2, Laurence Albiges3, Thomas Powles4, Brian I Rini5, Robert J Motzer6, Daniel Y C Heng7, Bernard Escudier3. 1. Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: gdevelasco.gdv@gmail.com. 2. Royal Free London NHS Fountation Turst, London, UK; UCL DIvision of Surgery and Interventional Science, London, UK. 3. Institut Gustave Roussy, Villejuif, France. 4. Barts Cancer Institute, London, UK. 5. Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. 6. Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 7. Tom Baker Cancer Center, Calgary, Canada.
Abstract
CONTEXT: Introduction of additional new agents targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs) has completely modified the systemic treatment of metastatic renal cell carcinoma (mRCC) during the last years. OBJECTIVE: A comprehensive (nonsystematic) review to determine the suggested sequence or combinations for the systemic treatment of mRCC. EVIDENCE ACQUISITION: PubMed and abstracts from main conferences up to December 2018 were reviewed to retrieve the current evidence for treatment of mRCC. Search terms included renal cell carcinoma, systemic therapy, targeted therapy (TT), and immunotherapy. EVIDENCE SYNTHESIS: Marked advances in the treatment of mRCC have been made with novel VEGFR tyrosine kinase inhibitors and multiple ICIs that have been included in the current treatment paradigm of mRCC. Remarkable advance has been made with the combination of double checkpoint blockade. The combination of ipilimumab and nivolumab compared with sunitinib has shown to increase the overall survival in the intermediate- and poor-risk patients based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. CONCLUSIONS: Double checkpoint blockade with ipilimumab and nivolumab has reported overall survival benefit in IMDC intermediate- and poor-risk patients, providing a durable response for a subset of patients. VEGF inhibitors remain the standard of care for favorable-risk patients in the first line. In the immediate future, more consolidated data on combination of VEGF-TT plus ICIs may show similar robust benefit with different safety profiles. PATIENT SUMMARY: Multiple drugs and sequences are now accepted as effective treatment for metastatic renal cell carcinoma (mRCC). Combination of immune checkpoint inhibitors has shown to increase the overall survival in treatment-naïve mRCC patients. Combinations of immunotherapy and antiangiogenics may be another option in the near future. Outcomes of the first line will determine the sequence, although the best sequence has yet to be defined.
CONTEXT: Introduction of additional new agents targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs) has completely modified the systemic treatment of metastatic renal cell carcinoma (mRCC) during the last years. OBJECTIVE: A comprehensive (nonsystematic) review to determine the suggested sequence or combinations for the systemic treatment of mRCC. EVIDENCE ACQUISITION: PubMed and abstracts from main conferences up to December 2018 were reviewed to retrieve the current evidence for treatment of mRCC. Search terms included renal cell carcinoma, systemic therapy, targeted therapy (TT), and immunotherapy. EVIDENCE SYNTHESIS: Marked advances in the treatment of mRCC have been made with novel VEGFR tyrosine kinase inhibitors and multiple ICIs that have been included in the current treatment paradigm of mRCC. Remarkable advance has been made with the combination of double checkpoint blockade. The combination of ipilimumab and nivolumab compared with sunitinib has shown to increase the overall survival in the intermediate- and poor-risk patients based on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. CONCLUSIONS: Double checkpoint blockade with ipilimumab and nivolumab has reported overall survival benefit in IMDC intermediate- and poor-risk patients, providing a durable response for a subset of patients. VEGF inhibitors remain the standard of care for favorable-risk patients in the first line. In the immediate future, more consolidated data on combination of VEGF-TT plus ICIs may show similar robust benefit with different safety profiles. PATIENT SUMMARY: Multiple drugs and sequences are now accepted as effective treatment for metastatic renal cell carcinoma (mRCC). Combination of immune checkpoint inhibitors has shown to increase the overall survival in treatment-naïve mRCC patients. Combinations of immunotherapy and antiangiogenics may be another option in the near future. Outcomes of the first line will determine the sequence, although the best sequence has yet to be defined.
Authors: Giuseppe Rosiello; Angela Pecoraro; Marina Deuker; Lara Franziska Stolzenbach; Thomas Martin; Zhe Tian; Alessandro Larcher; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Anil Kapoor; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Int J Clin Oncol Date: 2021-01-30 Impact factor: 3.402
Authors: Andreas Varkaris; Wenxin Xu; Roger B Davis; Brian Healy; David F McDermott Journal: Clin Genitourin Cancer Date: 2019-12-05 Impact factor: 2.872
Authors: Nirmish Singla; Zhiqun Xie; Ze Zhang; Ming Gao; Qurratulain Yousuf; Oreoluwa Onabolu; Tiffani McKenzie; Vanina Toffessi Tcheuyap; Yuanqing Ma; Jacob Choi; Renee McKay; Alana Christie; Oscar Reig Torras; Isaac A Bowman; Vitaly Margulis; Ivan Pedrosa; Christopher Przybycin; Tao Wang; Payal Kapur; Brian Rini; James Brugarolas Journal: JCI Insight Date: 2020-04-09
Authors: Andrea B Apolo; Rosa Nadal; Daniel M Girardi; Scot A Niglio; Lisa Ley; Lisa M Cordes; Seth M Steinberg; Olena Sierra Ortiz; Jacqueline Cadena; Carlos Diaz; Marissa Mallek; Nicole N Davarpanah; Rene Costello; Jane B Trepel; Min-Jung Lee; Maria J Merino; Mohammad Hadi Bagheri; Paul Monk; William D Figg; James L Gulley; Piyush K Agarwal; Vladimir Valera; Heather J Chalfin; Jennifer Jones; Howard Streicher; John J Wright; Yangmin M Ning; Howard L Parnes; William L Dahut; Donald P Bottaro; Primo N Lara; Biren Saraiya; Sumanta K Pal; Mark N Stein; Amir Mortazavi Journal: J Clin Oncol Date: 2020-09-11 Impact factor: 44.544
Authors: Sara Elena Rebuzzi; Alessio Signori; Giuseppe Luigi Banna; Marco Maruzzo; Ugo De Giorgi; Paolo Pedrazzoli; Andrea Sbrana; Paolo Andrea Zucali; Cristina Masini; Emanuele Naglieri; Giuseppe Procopio; Sara Merler; Laura Tomasello; Lucia Fratino; Cinzia Baldessari; Riccardo Ricotta; Stefano Panni; Veronica Mollica; Maria Sorarù; Matteo Santoni; Alessio Cortellini; Veronica Prati; Hector Josè Soto Parra; Marco Stellato; Francesco Atzori; Sandro Pignata; Carlo Messina; Marco Messina; Franco Morelli; Giuseppe Prati; Franco Nolè; Francesca Vignani; Alessia Cavo; Giandomenico Roviello; Francesco Pierantoni; Chiara Casadei; Melissa Bersanelli; Silvia Chiellino; Federico Paolieri; Matteo Perrino; Matteo Brunelli; Roberto Iacovelli; Camillo Porta; Sebastiano Buti; Giuseppe Fornarini Journal: Ther Adv Med Oncol Date: 2021-05-18 Impact factor: 8.168